Mary Mullen

Medicine & Life Sciences

1. Acute Chest Syndrome 17%
2. Anticoagulants 10%
3. Bevacizumab 11%
4. Biomarkers 17%
5. Carboplatin 10%
6. Cell Line 10%
7. Cytoreduction Surgical Procedures 14%
8. Discoidin Domain Receptor 2 20%
9. DNA Damage 21%
10. DNA Repair 11%
11. Drug Therapy 22%
12. Endometrial Neoplasms 60%
13. Extracellular Matrix Proteins 12%
14. Fluorescent Antibody Technique 10%
15. Frailty 26%
16. Glycolysis 13%
17. Gynecologic Surgical Procedures 23%
18. Homologous Recombination 21%
19. Hospices 21%
20. Hysterectomy 16%
21. Immunohistochemistry 11%
22. Immunotherapy 20%
23. Inpatients 14%
24. Intra-Abdominal Fat 12%
25. Medical Oncology 20%
26. Mutation 12%
27. Neoplasm Metastasis 11%
28. Neoplasms 47%
29. Organoids 48%
30. Ovarian Epithelial Carcinoma 13%
31. Ovarian Neoplasms 100%
32. Paclitaxel 13%
33. Palliative Care 22%
34. Pandemics 12%
35. Pelvis 11%
36. Placental Site Trophoblastic Tumor 18%
37. Platinum 30%
38. Poly(ADP-ribose) Polymerase Inhibitors 15%
39. Progestins 10%
40. Referral and Consultation 11%
41. Sexually Transmitted Diseases 11%
42. Subcutaneous Fat 12%
43. Survival 26%
44. Sutures 10%
45. Terminal Care 13%
46. Therapeutics 11%
47. Tumor Burden 12%
48. Uterine Neoplasms 16%
49. Vulvar Neoplasms 16%
50. Wounds and Injuries 16%